Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival

Hanna Engqvist; Toshima Z. Parris; Elisabeth Werner Rönnerman; Elin M.V. Söderberg; Jana Biermann; Claudia Mateoiu; Karin Sundfeldt; Anikó Kovács; Per Karlsson; Khalil Helou

doi:10.18632/oncotarget.26225

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival

Hanna Engqvist _, Toshima Z. Parris, Elisabeth Werner Rönnerman, Elin M.V. Söderberg, Jana Biermann, Claudia Mateoiu, Karin Sundfeldt, Anikó Kovács, Per Karlsson and Khalil Helou

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:35162-35180. https://doi.org/10.18632/oncotarget.26225

Metrics: PDF 1800 views | HTML 3132 views | ?

Abstract

Hanna Engqvist1, Toshima Z. Parris1, Elisabeth Werner Rönnerman1,2, Elin M.V. Söderberg3, Jana Biermann1, Claudia Mateoiu2, Karin Sundfeldt4, Anikó Kovács2, Per Karlsson1,* and Khalil Helou1,*

1Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

2Sahlgrenska University Hospital, Department of Clinical Pathology and Genetics, Gothenburg, Sweden

3Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

4Department of Obstetrics and Gynecology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

*These authors have contributed equally to this work

Correspondence to:

Hanna Engqvist, email: [email protected]

Keywords: ovarian cancer; diagnostic biomarker; prognostic biomarker; genomics

Received: June 13, 2018 Accepted: September 01, 2018 Published: October 12, 2018

ABSTRACT

Ovarian cancer is the most lethal gynecological malignancy in the western world. Despite recent efforts to characterize ovarian cancer using molecular profiling, few targeted treatment options are currently available. Here, we examined genetic variants, fusion transcripts, SNP genotyping, and gene expression patterns for early-stage (I and II) ovarian carcinomas (n=96) in relation to clinicopathological characteristics and clinical outcome, thereby identifying novel genetic features of ovarian carcinomas. Furthermore, mutation frequencies of specific genetic variants and/or their gene expression patterns were associated with histotype and overall survival, e.g. SLC28A2 (mucinous ovarian carcinoma histotype), ARCN1 (low expression in 0-2 year survival group), and tumor suppressor MTUS1 (mutation status and overall survival). The long non-coding RNA MALAT1 was identified as a highly promiscuous fusion transcript in ovarian carcinoma. Moreover, gene expression deregulation for 23 genes was associated with tumor aggressiveness. Taken together, the novel biomarkers identified here may improve ovarian carcinoma subclassification and patient stratification according to histotype and overall survival.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26225

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

Transcriptomic and genomic profiling of early-stage ovarian carcinomas associated with histotype and overall survival

Abstract